Ginkgo Bioworks Holdings, Inc. DNA

What this company does

Ginkgo Bioworks Holdings, Inc. does not make end products; instead, it offers biological research and development services on its platform to enable its customers to bring their products to market. As of December 31, 2025, the company had 485 employees. Its operations are anchored by Ginkgo's headquarters in Boston, which serves as a hub for managing its programs and analyzing data from its global network. It sells services to government and commercial customers in two business segments: cell engineering, where it provides tools and biological research and development services across a range of industries, and biosecurity, where it provides services to customers working to identify, monitor, prevent and mitigate biological threats. Within the cell engineering segment, its primary service offering has historically been cell engineering research and development services performed by Ginkgo, and since 2024 it has also offered cell engineering tools that let customers conduct certain in-house research and development activities themselves. Within the biosecurity segment, it provides two core offerings: Canopy, which generates genomic data from strategically positioned nodes such as airports and border checkpoints through biomonitoring programs, and Horizon, a digital surveillance, analytics and insights platform that detects and monitors biothreats worldwide.

Written from the business description in Ginkgo Bioworks Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.